Leerink Swann restated their outperform rating on shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in a research note published on Thursday morning. They currently have a $127.00 price target on the stock.

A number of other analysts have also recently issued reports on BMRN. Barclays PLC reaffirmed a buy rating on shares of BioMarin Pharmaceutical in a research report on Thursday, June 16th. Oppenheimer Holdings Inc. reiterated a market perform rating and set a $99.00 target price on shares of BioMarin Pharmaceutical in a research note on Monday, June 20th. Zacks Investment Research upgraded BioMarin Pharmaceutical from a hold rating to a buy rating and set a $98.00 target price on the stock in a research note on Wednesday, July 13th. Robert W. Baird increased their target price on BioMarin Pharmaceutical from $110.00 to $115.00 and gave the stock an outperform rating in a research note on Thursday, July 28th. Finally, Cowen and Company reiterated a buy rating on shares of BioMarin Pharmaceutical in a research note on Thursday, July 28th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $118.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 1.76% during trading on Thursday, reaching $85.34. The company’s stock had a trading volume of 385,658 shares. The company’s 50 day moving average price is $94.91 and its 200-day moving average price is $89.49. BioMarin Pharmaceutical has a 1-year low of $62.12 and a 1-year high of $118.48. The stock’s market cap is $13.95 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 4th. The company reported ($2.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $2.09. BioMarin Pharmaceutical had a negative net margin of 54.53% and a negative return on equity of 11.99%. The business earned $300.10 million during the quarter, compared to analyst estimates of $278.75 million. During the same period in the previous year, the business earned ($0.51) earnings per share. The business’s quarterly revenue was up 20.0% on a year-over-year basis. Equities analysts forecast that BioMarin Pharmaceutical will post ($3.95) earnings per share for the current fiscal year.

In other news, EVP George Eric Davis sold 2,167 shares of the firm’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $100.00, for a total transaction of $216,700.00. Following the transaction, the executive vice president now directly owns 71,158 shares of the company’s stock, valued at $7,115,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brian Mueller sold 287 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $100.00, for a total value of $28,700.00. Following the transaction, the vice president now directly owns 14,260 shares in the company, valued at $1,426,000. The disclosure for this sale can be found here. 2.50% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in BMRN. Pacer Advisors Inc. boosted its position in shares of BioMarin Pharmaceutical by 1.2% in the second quarter. Pacer Advisors Inc. now owns 4,339 shares of the company’s stock worth $338,000 after buying an additional 52 shares during the period. Hartford Investment Management Co. boosted its position in shares of BioMarin Pharmaceutical by 2.5% in the second quarter. Hartford Investment Management Co. now owns 2,906 shares of the company’s stock worth $226,000 after buying an additional 70 shares during the period. Essex Investment Management Co. LLC boosted its position in shares of BioMarin Pharmaceutical by 0.6% in the second quarter. Essex Investment Management Co. LLC now owns 15,411 shares of the company’s stock worth $1,199,000 after buying an additional 90 shares during the period. Mn Services Vermogensbeheer B.V. boosted its position in shares of BioMarin Pharmaceutical by 2.3% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 4,082 shares of the company’s stock worth $286,000 after buying an additional 90 shares during the period. Finally, Glenmede Trust Co. NA boosted its position in shares of BioMarin Pharmaceutical by 0.7% in the second quarter. Glenmede Trust Co. NA now owns 16,639 shares of the company’s stock worth $1,293,000 after buying an additional 114 shares during the period. 93.02% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.